Your session is about to expire
← Back to Search
Unknown
AG-80308 for Dry Eye Syndrome
Phase 1
Waitlist Available
Research Sponsored by Allgenesis Biotherapeutics Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial tests AG-80308 eye drops in patients with dry eye to see if it helps lubricate their eyes and reduce discomfort.
Eligible Conditions
- Dry Eye Syndrome
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
4Treatment groups
Experimental Treatment
Group I: Group 4Experimental Treatment1 Intervention
One drop of 0.03% AG-80308, new formulation, two times daily to both eyes for 3 months
Group II: Group 3Experimental Treatment1 Intervention
One drop of 0.1% AG-80308, two times daily to both eyes for 3 months
Group III: Group 2Experimental Treatment1 Intervention
One drop of 0.03% AG-80308, two times daily to both eyes for 3 months
Group IV: Group 1Experimental Treatment1 Intervention
One drop of 0.001% AG-80308, two times daily to both eyes for 3 months
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AG-80308
2022
Completed Phase 1
~90
Find a Location
Who is running the clinical trial?
Allgenesis Biotherapeutics Inc.Lead Sponsor
2 Previous Clinical Trials
89 Total Patients Enrolled
ORA, Inc.Industry Sponsor
69 Previous Clinical Trials
8,875 Total Patients Enrolled
Other Trials to Consider
Popular Categories
Learn More About These Treatments
Share this study with friends
Copy Link
Messenger